Heron Therapeutics (NASDAQ:HRTX) Announces Quarterly Earnings Results, Meets Expectations

Heron Therapeutics (NASDAQ:HRTX) announced its earnings results on Tuesday. The biotechnology company reported ($0.03) earnings per share for the quarter, hitting the consensus estimate of ($0.03), Zacks reports. The company had revenue of $32.81 million for the quarter, compared to analysts’ expectations of $36.40 million. During the same period last year, the business earned ($0.17) EPS. Heron Therapeutics updated its Q4 2024 guidance to EPS and its FY 2024 guidance to EPS.

Heron Therapeutics Stock Performance

NASDAQ HRTX opened at $1.22 on Thursday. The firm has a market cap of $185.04 million, a price-to-earnings ratio of -6.72 and a beta of 1.81. The firm has a 50 day simple moving average of $1.85 and a 200-day simple moving average of $2.53. Heron Therapeutics has a one year low of $0.72 and a one year high of $3.93.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. StockNews.com raised shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday. Needham & Company LLC lowered their price target on Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.